BRISBANE, Calif.--(BUSINESS WIRE)--Tercica, Inc. (Nasdaq:TRCA) today announced that it has entered into a new manufacturing agreement with Lonza Group Ltd., for the manufacturing and commercial supply of Increlex®, recombinant human insulin-like growth factor-1 (rhIGF-1).
